Skip to Content logo

Investor Overview

Our diverse pipeline combines a unique portfolio model with innovative sourcing techniques and drug development expertise to discover and advance candidates for potentially transformative, best- or first-in-class, early-stage clinical therapeutic asset for oncology.

Stock Performance



Data Provided by Refinitiv. Minimum 15 minutes delayed.